PreprintReviewVersion 1Preserved in Portico This version is not peer-reviewed
Managing Skin Ageing as a Modifiable Disorder – The Clinical Application of Nourella® Dual Approach Comprising a Nano-encapsulated Retinoid, Retilex-A® and a Skin Proteoglycan Replacement Therapy, Vercilex®
Version 1
: Received: 28 October 2021 / Approved: 2 November 2021 / Online: 2 November 2021 (10:55:27 CET)
How to cite:
Wadstein, J.; Alvarez, I.S.; Thom, E.; López, L.B. Managing Skin Ageing as a Modifiable Disorder – The Clinical Application of Nourella® Dual Approach Comprising a Nano-encapsulated Retinoid, Retilex-A® and a Skin Proteoglycan Replacement Therapy, Vercilex®. Preprints2021, 2021110043. https://doi.org/10.20944/preprints202111.0043.v1
Wadstein, J.; Alvarez, I.S.; Thom, E.; López, L.B. Managing Skin Ageing as a Modifiable Disorder – The Clinical Application of Nourella® Dual Approach Comprising a Nano-encapsulated Retinoid, Retilex-A® and a Skin Proteoglycan Replacement Therapy, Vercilex®. Preprints 2021, 2021110043. https://doi.org/10.20944/preprints202111.0043.v1
Wadstein, J.; Alvarez, I.S.; Thom, E.; López, L.B. Managing Skin Ageing as a Modifiable Disorder – The Clinical Application of Nourella® Dual Approach Comprising a Nano-encapsulated Retinoid, Retilex-A® and a Skin Proteoglycan Replacement Therapy, Vercilex®. Preprints2021, 2021110043. https://doi.org/10.20944/preprints202111.0043.v1
APA Style
Wadstein, J., Alvarez, I.S., Thom, E., & López, L.B. (2021). Managing Skin Ageing as a Modifiable Disorder – The Clinical Application of Nourella® Dual Approach Comprising a Nano-encapsulated Retinoid, Retilex-A® and a Skin Proteoglycan Replacement Therapy, Vercilex®. Preprints. https://doi.org/10.20944/preprints202111.0043.v1
Chicago/Turabian Style
Wadstein, J., Erling Thom and Lidia Bernal López. 2021 "Managing Skin Ageing as a Modifiable Disorder – The Clinical Application of Nourella® Dual Approach Comprising a Nano-encapsulated Retinoid, Retilex-A® and a Skin Proteoglycan Replacement Therapy, Vercilex®" Preprints. https://doi.org/10.20944/preprints202111.0043.v1
Abstract
Skin ageing is a progressive but modifiable, multi-factorial disorder that involves all skin tissues. Pertaining to its wide range of physiological and psychosocial complications, skin ageing requires rigorous clinical attention. Topical retinoids and per-oral proteoglycans are promising, non-invasive, therapeutic modalities. To overcome the low bioavailability of conventional free retinoids, Nourella® cream with Retilex-A® (Pharma Medico, Aarhus, Denmark) was developed using a proprietary nano-encapsulation technology. The nano-encapsulation is a sophisticated ‘permeation/penetration enhancer’ that optimises topical drug delivery by increasing surface availability and net absorption ratio. Treatment adherence is also improved by minimising skin irritation. Interventional evidence supports the higher efficacy of Retilex-A® in improving skin thickness and elasticity compared with conventional free forms. It is also reported that the rejuvenating efficacy of Retilex-A® and tretinoin are comparable. Another skin anti-ageing approach is proteoglycan replacement therapy (PRT) with Vercilex®. Vercilex® in Nourella® tablet has the potential to ameliorate proteoglycan dysmetabolism in the aged skin by activating skin cells and improving collagen/elastin turnover. Replicated clinical trials evidenced that PRT can significantly enhance the density, elasticity and thickness of both intrinsically aged and photoaged skin. Evidently, Vercilex® and Retilex-A® share a range of bioactivities, which underlies their synergistic activity observed in a clinical trial. Dual therapy with Nourella® tablets and cream produced higher effect sizes on skin characteristics than monotherapy with each of the two treatments. In conclusion, Nourella® cream and tablets are safe and effective treatments for skin ageing; however, combining the two in a ‘dual skin rejuvenation system’ significantly improves treatment outcomes.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
